Please login to the form below
Rinvoq
This page shows the latest Rinvoq news and features for those working in and with pharma, biotech and healthcare.
Incyte’s JAK inhibitor cream clears second eczema trial
The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
Latest news
-
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well ... Meanwhile, selective JAK inhibitor Rinvoq added another
-
AbbVie creates new aesthetics division amid Allergan takeover
This includes psoriasis treatment Skyrizi, Rinvoq, medical Botox, and cancer treatments Imbruvica and Veclexta.
-
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... Across these phase 3 studies, Rinvoq met all its primary and
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... ICER’s conclusion that Rinvoq, in particular, only had a ‘marginal’ benefit over
-
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
ICER’s original report concluded that the incremental cost-effectiveness of Rinvoq versus AbbVie’s ageing blockbuster Humira exceeded its $150, 000 threshold. ... According to ICER, this evidence demonstrates that Rinvoq provides a small to
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
AbbVie creates new aesthetics division amid Allergan takeover
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
JAK inhibitors such as Xeljanz and Rinvoq.
-
20 for 2020 – Five pharma companies to watch
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Cortellis Drugs to Watch in 2020 report
20 for 2020 – Five pharma companies to watch
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Publications Director
-
Competitive Salary
-
Planner
-
Salary TBC
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Novartis’ iptacopan scores positive results in rare blood disorder PNH
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
- Fishawack Health acquires digital marketing agency closerlook
- Biotech Innovation in the Time of COVID-19
- Using Technology to Improve Patient Experience
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease
- Diversity and inclusion in clinical trials
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- EMA authorises Pfizer/BioNTech’s COVID-19 vaccine for children aged 12 to 15
- FDA lifts clinical hold on bluebird bio’s LentiGlobin studies
- Fishawack Health acquires digital marketing agency closerlook
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
- Why empathy in digital patient recruitment is vital
- This is where empathy mapping can be incredibly effective....
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
